Denileukin diftitox [clinicaltrials_resource:dfc6871cb493e3120580022a05780922]
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma [clinicaltrials:NCT00003615]Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma [clinicaltrials:NCT00006345]Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma [clinicaltrials:NCT00026429]Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00056134]clinicaltrials:NCT00082758Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer [clinicaltrials:NCT00082914]Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia [clinicaltrials:NCT00082940]clinicaltrials:NCT00117845clinicaltrials:NCT00128622clinicaltrials:NCT00138164A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma [clinicaltrials:NCT00211185]Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) [clinicaltrials:NCT00211198]A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma [clinicaltrials:NCT00211276]clinicaltrials:NCT00224874Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine [clinicaltrials:NCT00228358]Effect of Denileukin Diftitox on Immune System in CTCL Patients [clinicaltrials:NCT00254332]Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer [clinicaltrials:NCT00278369]clinicaltrials:NCT00299689Combination Daclizumab/Denileukin Diftitox to Treat Uveitis [clinicaltrials:NCT00326508]clinicaltrials:NCT00337987clinicaltrials:NCT00357448clinicaltrials:NCT00425672clinicaltrials:NCT00460109Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) [clinicaltrials:NCT00493129]Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma [clinicaltrials:NCT00513188]Vaccination Plus Ontak in Patients With Metastatic Melanoma [clinicaltrials:NCT00515528]Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) [clinicaltrials:NCT00632827]clinicaltrials:NCT00703105clinicaltrials:NCT00726037Denileukine Diftitox for Relapsed ALCL [clinicaltrials:NCT00801918]clinicaltrials:NCT00880360clinicaltrials:NCT00945269clinicaltrials:NCT01106950clinicaltrials:NCT01127451clinicaltrials:NCT01251952E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma [clinicaltrials:NCT01401530]Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak) [clinicaltrials:NCT01432483]clinicaltrials:NCT01773889Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients After Regulatory T Cell Depletion With Denileukin Diftitox [clinicaltrials:NCT02009384]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Denileukin diftitox [clinicaltrials_resource:dfc6871cb493e3120580022a05780922]
Bio2RDF identifier
dfc6871cb493e3120580022a05780922
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:dfc6871cb493e3120580022a05780922
identifier
clinicaltrials_resource:dfc6871cb493e3120580022a05780922
title
Denileukin diftitox
@en
type
label
Denileukin diftitox [clinicaltrials_resource:dfc6871cb493e3120580022a05780922]
@en